Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1850 of 4090 results for patient

  1. Gynaecological conditions: rates of endometrial ablation (heavy menstrual bleeding) (IND59)

    This indicator covers rates of endometrial ablation. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG78

    Network / system level indicators
    Last updated
    22 March 2024

  2. TopClosure Tension Relief System for wound closure (MIB97)

    NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .

    Medtech innovation briefing
    Published
    7 March 2017

  3. Further research into joint distraction for ankle osteoarthritis should include comparative studies against the natural history of the disease and against other forms of management. Studies should record patient selection, pain relief, functional outcomes, complications, and quality of life in the long term. They should also report the nature and timing of any further surgery on the ankle.Minimising loss to follow-up is of particular importance. NICE may update the guidance on publication of further evidence.

    the disease and against other forms of management. Studies should record patient selection, pain relief, functional outcomes,...

    Research recommendation
    Published
    25 January 2016

  4. NICE encourages further research into ultrasound-enhanced, catheter-directedthrombolysis for pulmonary embolism. Ideally this should include comparative studies against catheter-directed thrombolysis alone. Patient selection should be  documented. The dose of thrombolytic agent used and the duration of thrombolysis should be reported, together with all complications. Outcome measures should include the success of thrombolysis (complete, partial or failed) and long-term sequelae. NICE may update the guidance on publication of further evidence.

    include comparative studies against catheter-directed thrombolysis alone. Patient selection should be documented. The dose of...

    Research recommendation
    Published
    6 October 2015

  5. Acute coronary syndromes in adults (QS68)

    This quality standard covers diagnosing and managing acute coronary syndromes in adults (aged 18 and over). Acute coronary syndromes are medical emergencies that include myocardial infarction (heart attack) and unstable angina (unexpected, severe chest pain). It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    18 November 2020
    View quality statements

    Sections for QS68

  6. Erenumab for preventing migraine (TA682)

    Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    10 March 2021
    View recommendations

    Sections for TA682

  7. Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template (PMG24)

    This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies evaluations process. It explains what information NICE requires and the format in which it should be presented

  8. Cost comparison timeline

    These are the main stages in the multiple technology appraisal process used before April 2018.

  9. Stretta System for gastro-oesophageal reflux disease (MIB74)

    NICE has developed a medtech innovation briefing (MIB) on the Stretta System for gastro-oesophageal reflux disease

    Medtech innovation briefing
    Published
    26 July 2016

  10. Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment (HTG713)

    Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.

    HealthTech guidance
    Published
    25 March 2024
    View recommendations

    Sections for HTG713

  11. Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias (MIB276)

    NICE has developed a medtech innovation briefing (MIB) on Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias .

    Medtech innovation briefing
    Published
    14 September 2021

  12. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  13. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  14. NICE encourages further research comparing ultrasound-enhanced, catheter-directed thrombolysis for deep vein thrombosis against catheter-directed thrombolysis alone. Patient selection should be documented, including the duration and extent of thrombosis. The dose of thrombolytic agent used and the duration of thrombolysis should be reported, together with all complications. Outcome measures should include the success of thrombolysis (complete, partial or failed) and long-term sequelae. NICE may update the guidance on publication of further evidence.

    for deep vein thrombosis against catheter-directed thrombolysis alone. Patient selection should be documented, including the duration...

    Research recommendation
    Published
    5 October 2015

  15. Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation (HTG771)

    Evidence-based recommendations on transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation. This involves putting an artificial valve inside the existing faulty valve.

    HealthTech guidance
    Published
    25 February 2026
    View recommendations

    Sections for HTG771

  16. Multiple long-term conditions: multimorbidity register (IND205)

    This indicator covers the practice can produce a register of people with multimorbidity who would benefit from a tailored approach to care. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM184

    General practice indicators suitable for use in QOF
    Published
    31 July 2019

  17. Stroke and ischaemic attack: early supported discharge (IND32)

    This indicator covers the proportion of people who had a stroke that are supported by a skilled stroke early supported discharge team. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG49

    Network / system level indicators
    Last updated
    18 October 2023

  18. Heart failure: ejection fraction category (IND318)

    This indicator covers the percentage of patients with a diagnosis of heart failure on or after 1 April 2026 who have a recorded ejection fraction category (reduced, mildly reduced, or preserved). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    General practice indicators suitable for use in QOF
    Published
    11 November 2025

  19. Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)

    Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy.

    Technology appraisal guidance
    Published
    21 October 2020
    View recommendations

    Sections for TA655

  20. Image-guided vacuum-assisted excision biopsy of benign breast lesions (HTG100)

    Evidence-based recommendations on aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease in adults. This involves replacing the diseased part of the valve with some of the person’s own pericardium.

    HealthTech guidance
    Published
    22 February 2006
    View recommendations

    Sections for HTG100

  21. Accessing NHS care and treatment recommended by NICE (ECD4)

    This document contains advice to help you access treatments and care that NICE has recommended

  22. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    11 February 2016
    View quality statements

    Sections for QS114

  23. Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)

    Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.

    Technology appraisal guidance
    Published
    20 September 2023
    View recommendations

    Sections for TA914

  24. Endoscopic laser foraminoplasty (HTG13)

    Evidence-based recommendations on endoscopic laser foraminoplasty. This involves inserting a laser to remove portions of the disc that have protruded and are narrowing the foramen.

    HealthTech guidance
    Published
    17 December 2003
    View recommendations

    Sections for HTG13

  25. Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

    Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

    Evidence summary
    Published
    24 September 2013

  26. Extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome (HTG248)

    Evidence-based recommendations on extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome. This involves using a machine to deliver sound waves to the painful area to stimulate healing.

    HealthTech guidance
    Published
    26 January 2011
    View recommendations

    Sections for HTG248

  27. Superficial venous arterialisation for chronic limb threatening ischaemia (HTG637)

    Evidence-based recommendations on superficial venous arterialisation for chronic limb threatening ischaemia in adults. This involves joining an artery in the lower leg to a large vein to divert blood flow through the vein towards the foot, bypassing the blocked arteries.

    HealthTech guidance
    Published
    24 August 2022
    View recommendations

    Sections for HTG637

  28. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

    Medtech innovation briefing
    Published
    29 November 2016

  29. Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)

    Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.

    Technology appraisal guidance
    Published
    26 January 2011
    View recommendations

    Sections for TA213

  30. Balloon catheter dilation of paranasal sinus ostia for chronic sinusitis (HTG174)

    Evidence-based recommendations on balloon catheter dilation of paranasal sinus ostia for chronic sinusitis. This involves gently inflating a small balloon, which is introduced through the nose via a flexible tube, to help keep the sinus passages open and unobstructed.

    HealthTech guidance
    Published
    24 September 2008
    View recommendations

    Sections for HTG174

  31. Artificial intelligence for analysing CT brain scans (MIB207)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .

    Medtech innovation briefing
    Published
    17 March 2020

  32. OSNA for colon cancer staging (MIB77)

    NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging

    Medtech innovation briefing
    Published
    24 August 2016

  33. Percutaneous retroperitoneal endoscopic necrosectomy (HTG255)

    Evidence-based recommendations on percutaneous retroperitoneal endoscopic necrosectomy. This involves inserting a thin telescope through a small cut in the side above the hip and using it to wash out and remove the dead tissue.

    HealthTech guidance
    Published
    23 March 2011
    View recommendations

    Sections for HTG255

  34. Extracorporeal carbon dioxide removal for acute respiratory failure (HTG703)

    Evidence-based recommendations on extracorporeal carbon dioxide removal for acute respiratory failure. This involves taking blood out of the circulatory system and passing it across a synthetic membrane that allows some of the carbon dioxide in the blood to be removed. The blood is then returned to the circulatory system.

    HealthTech guidance
    Published
    15 November 2023
    View recommendations

    Sections for HTG703

  35. Technology appraisal submission templates and supporting documents

    All the templates and supporting documents you need to make a technology appraisals submission with NICE.

  36. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]

    In development Reference number: GID-TA11429 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  37. Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia in remission with minimal residual disease activity in adults.

    Technology appraisal guidance
    Published
    24 July 2019
    View recommendations

    Sections for TA589

  38. NICE encourages further research on endovascular aneurysm sealing for abdominal aortic aneurysmthis procedure in the form of controlled clinical trials, observational studies and analysis of registry data. Details about patient selection, including anatomical details, should be clearly documented.Research should compare the procedure with conventional stent graft endovascular aneurysm repair. All complications should be reported. Long-term outcomes should be described as data become available. NICE may update the guidance on publication of further evidence.

    trials, observational studies and analysis of registry data. Details about patient selection, including anatomical details, should be...

    Research recommendation
    Published
    21 March 2016

  39. Circular stapled haemorrhoidectomy (HTG15)

    Evidence-based recommendations on circular stapled haemorrhoidectomy. This involves cutting out a circular strip of the lining of the rectum (the rectal mucosa) above the haemorrhoids to reduce the blood supply to the haemorrhoids, so that they shrink.

    HealthTech guidance
    Published
    17 December 2003
    View recommendations

    Sections for HTG15

  40. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.

    Technology appraisal guidance
    Published
    27 January 2016
    View recommendations

    Sections for TA378

  41. Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)

    NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .

    Medtech innovation briefing
    Published
    21 May 2020

  42. Cryotherapy for recurrent prostate cancer (HTG71)

    Evidence-based recommendations on cryotherapy for treating recurrent prostate cancer. This involves putting special needles or probes into the prostate and using Argon gas to freeze and destroy the cancerous prostate tissue.

    HealthTech guidance
    Published
    25 May 2005
    View recommendations

    Sections for HTG71

  43. Heavy menstrual bleeding: assessment and management (NG88)

    This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.

    NICE guideline
    Last updated
    24 May 2021
    View recommendations

    Sections for NG88

  44. Healthcare-associated infections: readmission rates (IND60)

    This indicator covers readmission rates for surgical site infections within 30 days of discharge from surgery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG79

    Network / system level indicators
    Last updated
    3 November 2020

  45. HemaClear for bloodless surgical field during limb surgery (MIB187)

    NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .

    Medtech innovation briefing
    Published
    15 July 2019

  46. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (HTG348)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).

    HealthTech guidance
    Published
    20 August 2014
    View recommendations

    Sections for HTG348

  47. Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)

    Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.

    Technology appraisal guidance
    Published
    20 August 2025

    Sections for TA1091

  48. Fever in under 5s: assessment and initial management (NG143)

    This guideline covers the assessment and early management of fever with no obvious cause in children aged under 5. It aims to improve clinical assessment and help healthcare professionals diagnose serious illness among young children who present with fever in primary and secondary care.

    NICE guideline
    Last updated
    26 November 2021
    View recommendations

    Sections for NG143

  49. Galaxy UNYCO for temporary stabilisation of lower limb fractures (MIB166)

    NICE has developed a medtech innovation briefing (MIB) on Galaxy UNYCO for temporary stabilisation of lower limb fractures .

    Medtech innovation briefing
    Published
    14 December 2018

  50. Percutaneous cryotherapy for renal cancer (HTG269)

    Evidence-based recommendations on percutaneous cryotherapy for renal tumours. This involves inserting instruments that apply cold temperatures into the tumour to destroy the cancer cells.

    HealthTech guidance
    Published
    27 July 2011
    View recommendations

    Sections for HTG269